These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 8913832)
21. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
22. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
23. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer. Norton L Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263 [TBL] [Abstract][Full Text] [Related]
24. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
25. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells. Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311 [TBL] [Abstract][Full Text] [Related]
26. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Frei E; Ara G; Teicher B; Bunnell C; Richardson P; Wheeler C; Tew K; Elias A Cancer Chemother Pharmacol; 2000; 45(3):239-46. PubMed ID: 10663642 [TBL] [Abstract][Full Text] [Related]
27. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320 [TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life in early breast cancer. Groenvold M Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024 [TBL] [Abstract][Full Text] [Related]
29. Multidrug resistance: molecular mechanisms and clinical relevance. Ling V Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126 [TBL] [Abstract][Full Text] [Related]
30. Drug resistance in chemotherapy for breast cancer. Saeki T; Tsuruo T; Sato W; Nishikawsa K Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361 [TBL] [Abstract][Full Text] [Related]
31. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709 [TBL] [Abstract][Full Text] [Related]
32. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Benedetti Panici P; Greggi S; Amoroso M; Scambia G; Battaglia FA; Gebbia V; Salerno G; Paratore MP; Mancuso S Int J Gynecol Cancer; 2001; 11(6):438-44. PubMed ID: 11906546 [TBL] [Abstract][Full Text] [Related]
33. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. Leijen S; van Geel RM; Sonke GS; de Jong D; Rosenberg EH; Marchetti S; Pluim D; van Werkhoven E; Rose S; Lee MA; Freshwater T; Beijnen JH; Schellens JH J Clin Oncol; 2016 Dec; 34(36):4354-4361. PubMed ID: 27998224 [TBL] [Abstract][Full Text] [Related]
34. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319 [TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Evans WE Blut; 1988 Jun; 56(6):241-8. PubMed ID: 3289632 [TBL] [Abstract][Full Text] [Related]
36. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U; Wilke H; Seeber S Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Ludwig R; Alberts DS; Miller TP; Salmon SE Cancer Chemother Pharmacol; 1984; 12(3):135-41. PubMed ID: 6705130 [TBL] [Abstract][Full Text] [Related]
38. The effect of brassinolide, a plant steroid hormone, on drug resistant small-cell lung carcinoma cells. Sadava D; Kane SE Biochem Biophys Res Commun; 2017 Nov; 493(1):783-787. PubMed ID: 28847728 [TBL] [Abstract][Full Text] [Related]
39. Chemosensitization of solid tumors by modulation of resistance mechanisms. Cree IA; Knight L; Di Nicolantonio F; Sharma S; Gulliford T Curr Opin Investig Drugs; 2002 Apr; 3(4):634-40. PubMed ID: 12090736 [TBL] [Abstract][Full Text] [Related]
40. Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. Wilson WH; Little R; Pearson D; Jaffe ES; Steinberg SM; Cheson BD; Humphrey R; Kohler DR; Elwood P J Clin Oncol; 1998 Jul; 16(7):2345-51. PubMed ID: 9667249 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]